Loading
A phase 2 trial of Masofaniten and Enzalutamide in Metastatic hormone-sensitive prostate cancer and Prostate cancer, run by Pedro Barata, MD, MSc, completed.
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer is a phase 2 interventional study registered as NCT06312670 by Pedro Barata, MD, MSc, with 13 participants recorded, started 2024-05-16 and reaching its primary completion in 2025-01-09. Interventions recorded: EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT). Conditions recorded: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma.
Linked to the drug Masofaniten because the registry names it among its interventions and Metastatic hormone-sensitive prostate cancer and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer and the tag pipeline.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/